accountthe product, while Daiichi Sankyo will be responsible for distribution. Underscoring the increasing importance of the Japanese market, GlaxoSmithKline said on Friday it had received approval there for blood disorder treatment Revolade, and for its...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to AstraZeneca, Daiichi to co-promote Nexium in Japan
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account